Scalper1 News
The annual meeting of the American Association for Cancer Research, which convenes in San Diego on April 5, is viewed by most drug-industry watchers as a second-tier medical conference. But physicians and investors will be watching closely this year, as Pfizer will report on a drug that could dramatically extend the lives of patients with breast cancer. Pfizer’s (PFE) palbociclib is the first in a new class of cancer drugs called CDK 4/6 Scalper1 News
Scalper1 News